Myriad Genetics Inc. (MYGN) Insider Trading

Last 12 months

Insiders bought $722k and sold $67k on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

+$655k

3 buys · 1 sale

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

3 / 1

executives and directors

Last open-market buy

May 2026

May 14, 2026

Get an email when MYGN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 8	Rashmi Kumar Director	Sold10b5-1 plan	15,000	$4.46	$67k	8.0%	Form 4
May 14	Paul Bisaro Director	Bought	7,500	$3.69	$28k	8.3%	Form 4
Mar 9	Samraat S. Raha President and CEO	Bought	40,000	$5.00	$200k	8.8%	Form 4
Feb 25 – 27	S. Louise Phanstiel Director	Bought 3 parts	104,507	$4.73 average	$495k	50%	Form 4

Jun 810b5-1 plan
Rashmi Kumar
Director · sold 15,000 at $4.46
$67k
8.0% of stake
May 14
Paul Bisaro
Director · bought 7,500 at $3.69
$28k
8.3% of stake
Mar 9
Samraat S. Raha
President and CEO · bought 40,000 at $5.00
$200k
8.8% of stake
Feb 25 – 27
S. Louise Phanstiel
Director · bought 104,507 at avg $4.73
$495k
50% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MYGN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: In Vitro & In Vivo Diagnostic Substances

NEOGNeogen Corporation

LNTHLantheus Holdings, Inc.

QDELQuidelOrtho Corporation

IDXXIDEXX Laboratories, Inc.

COLLCollegium Pharmaceutical Inc.

TGTXTG Therapeutics, Inc.

RGENRepligen Corporation

SUPNSupernus Pharmaceuticals Inc.

Spot a number that looks wrong? Check it in MYGN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MYGN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.